#27 When drugs damage the liver – Rita Baião

Drug Safety Matters

The liver is the primary site for drug metabolism in the body, but it can be severely damaged by medicines or their toxic compounds. Rita Baião from the North Lisbon University Hospital Center reviews what pharmacovigilance professionals should know about drug-induced liver injury (DILI).
Tune in to find out:

• Who is most at risk of developing DILI
• How to diagnose the condition and control the damage
• How to assess case reports of DILI

Want to know more?

• This infographic in Nature Reviews nicely summarises the mechanisms, diagnosis, and management of drug-induced liver injury.
• In this report, the Council for International Organizations of Medical Sciences provides a global perspective on DILI detection, susceptibility factors, outcomes, and more.
• In this Drug Safety article, industry representatives outline how to identify, mitigate, and communicate the risk of DILI during drug development.
• The PRO-EURO DILI NETWORK coordinates research efforts on DILI across Europe and provides a forum to exchange knowledge and training on the topic. Similar initiatives include the Spanish DILI Registry and the Latin American DILI Network.
• The free online tool LiverTox contains up-to-date information on drug-induced liver injury for medicines and herbal products.

To learn more about post-marketing surveillance and clinical care of DILI, check out Uppsala Monitoring Centre’s free online course on the topic.
For more on the clustering algorithm vigiGroup, revisit this interview with UMC scientists Jim Barrett and Joe Mitchell.

Join the conversation on social media
Follow us on X, LinkedIn, or Facebook and share your thoughts about the show with the hashtag #DrugSafetyMatters.
Got a story to share?
We’re always looking for new content and interesting people to interview. If you have a great idea for a show, get in touch!
About UMC
Read more about Uppsala Monitoring Centre and how we work to advance medicines safety.

章节

1. #27 When drugs damage the liver – Rita Baião (00:00:00)

2. Intro (00:00:15)

3. Welcome, Rita! (00:01:57)

4. Frequency of DILI (00:02:26)

5. Pre- and post-marketing (00:03:36)

6. Mechanisms of injury (00:05:21)

7. Risk factors (00:07:17)

8. Diagnosis (00:09:32)

9. Controlling the damage (00:11:43)

10. Impact on adherence (00:13:03)

11. Analysing DILI reports (00:17:14)

12. Patient registries (00:19:42)

13. Clustering DILI reports with vigiGroup (00:22:43)

14. Benefits of vigiGroup (00:24:57)

15. Outro (00:27:05)